Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer

Ovarian cancer is the second leading cause of cancer-related death in women worldwide. Despite optimal cytoreduction and adequate adjuvant therapies, initial tumor response is often followed by relapse suggesting the existence of a tumor niche. Targeted therapies have been evaluated in ovarian cancer to overcome resistant disease. Among them, antiangiogenic therapies inhibit new blood vessel growth, induce endothelial cell apoptosis, and block the incorporation of hematopoietic and endothelial progenitor cells into new blood vessels. Despite in vitro and in vivo successes, antivascular therapy with bevacizumab targeting VEGF-A has limited efficacy in ovarian cancer. The precise molecular mechanisms underlying clinical resistance to anti-VEGF therapies are not yet well understood. Among them, tumor and stromal heterogeneity might determine the treatment outcomes. The present study investigates whether abnormalities in the tumor endothelium may contribute to treatment resistance to bevacizumab and promote a residual microscopic disease. Here, we showed that ovarian cancer cells activate Akt phosphorylation in endothelial cells inducing resistance to bevacizumab leading to an autocrine loop based on FGF2 secretion. Altogether, our results point out the role of an activated endothelium in the resistance to bevacizumab and in the constitution of a niche for a residual disease. Mol Cancer Ther; 13(12); 3123–36. ©2014 AACR.

[1]  Mina J. Bissell,et al.  The perivascular niche regulates breast tumor dormancy , 2013, Nature Cell Biology.

[2]  V. Chekhonin,et al.  VEGF in tumor progression and targeted therapy. , 2013, Current cancer drug targets.

[3]  S. Rafii,et al.  Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance , 2013, Journal of Translational Medicine.

[4]  P. Hegde,et al.  Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab , 2012, Clinical Cancer Research.

[5]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[6]  Ronald G. Crystal,et al.  Endothelial-Derived Angiocrine Signals Induce and Sustain Regenerative Lung Alveolarization , 2011, Cell.

[7]  M. Wicha,et al.  Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. , 2010, Cancer research.

[8]  N. Ferrara,et al.  Targeting the tumour vasculature: insights from physiological angiogenesis , 2010, Nature Reviews Cancer.

[9]  T. Mikkelsen,et al.  Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma , 2010, Journal of Neuro-Oncology.

[10]  Shahin Rafii,et al.  Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors , 2010, Nature Reviews Cancer.

[11]  M. Falasca,et al.  A Phosphoinositide 3-Kinase/Phospholipase Cgamma1 Pathway Regulates Fibroblast Growth Factor-Induced Capillary Tube Formation , 2009, PloS one.

[12]  Yihai Cao,et al.  Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. , 2009, Seminars in cancer biology.

[13]  FedericaFinetti,et al.  Prostaglandin E2 Primes the Angiogenic Switch via a Synergic Interaction With the Fibroblast Growth Factor-2 Pathway , 2009 .

[14]  A. Grothey,et al.  Targeting angiogenesis: progress with anti-VEGF treatment with large molecules , 2009, Nature Reviews Clinical Oncology.

[15]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Ian A. White,et al.  Generation of a functional and durable vascular niche by the adenoviral E4ORF1 gene , 2008, Proceedings of the National Academy of Sciences.

[17]  W. Cacheux,et al.  Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  D. Hanahan,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[19]  R. Roskoski,et al.  Vascular endothelial growth factor (VEGF) signaling in tumor progression. , 2007, Critical reviews in oncology/hematology.

[20]  E. Voest,et al.  Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. , 2007, The oncologist.

[21]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[22]  G. Camussi,et al.  The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway , 2006, Journal of Molecular Medicine.

[23]  J. Au,et al.  Expression of Basic Fibroblast Growth Factor Correlates with Resistance to Paclitaxel in Human Patient Tumors , 2006, Pharmaceutical Research.

[24]  T. Hudson,et al.  From gene profiling to diagnostic markers: IL‐18 and FGF‐2 complement CA125 as serum‐based markers in epithelial ovarian cancer , 2006, International journal of cancer.

[25]  J. Testa,et al.  Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.

[26]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[27]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[28]  Dhara N. Amin,et al.  Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities , 2004, Cancer Research.

[29]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[30]  S. Rafii,et al.  Adenovirus E4 Gene Promotes Selective Endothelial Cell Survival and Angiogenesis via Activation of the Vascular Endothelial-Cadherin/Akt Signaling Pathway* , 2004, Journal of Biological Chemistry.

[31]  Z. Peng,et al.  [The effect of basic fibroblast growth factor in ovarian cancer growth and angiogenesis]. , 2003, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics.

[32]  Hui-ying Yu,et al.  [Expression of aFGF and bFGF in ovarian cancer and their effect on ovarian cancer cell proliferation]. , 2003, Ai zheng = Aizheng = Chinese journal of cancer.

[33]  Zhilan Peng,et al.  [An experimental research in the inhibiting effect of bFGF-MAb on the growth of ovarian cancer cells and transplanted tumor]. , 2003, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition.

[34]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[35]  Philippe Leboulch,et al.  Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.

[36]  J. Folkman.  Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[37]  M Roederer,et al.  Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. , 2001, Cytometry.

[38]  R. Busse,et al.  Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation , 1999, Nature.

[39]  S. Hubbard,et al.  Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain , 1998, The EMBO journal.

[40]  S. Hubbard,et al.  Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. , 1997, Science.

[41]  T. Tamaya,et al.  Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). , 1997, Cancer letters.

[42]  M. Mrugala,et al.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.

[43]  Yihai Cao.  Tumor angiogenesis and molecular targets for therapy. , 2009, Frontiers in bioscience.

[44]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[45]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.